一线用药的EGFR-TKIs与化疗治疗基因突变型NSCLC疗效比较的Meta分析-期刊.pdfVIP

· 566· 田壹茎 笠 二线用药的EGFR—TKIs与化疗治疗基因突变型NSCLC疗效比较的Meta分析 线 析 用药的EGFR—TKIs与化疗治疗基因突变型NSCLC疗效比较的Meta 田春琴 ，赵新汉 ，耿会生。，崔立春 ，王 旋 ，杜建飞 AMeta——analysisoneffectivenessofEGFR——TKIscomparedwithchemotherapyasfirst—— linetreatmentofEGFRmutation——selectednon——smallcelllungcancer Tian Chunqin一，ZhaoXinhan ，GengHuisheng ，CuiLichun。WangXuan ，DuJianfei ， OncologyDepartment，FirstAffiliatedHospitalofXianJiaotong University，ShaanxiXian710061，China；OncologyDepart ment；RadiotherapyCentre，theInternationalCooperationChang~nHospital，ShaanxiXittn710016，China． A【bstract】 objective：ToanalyzetheeffectivenessofEGFR—TKIscomparedwithchemotherapyasfirst—lineon theEGFRmutation—selectedpatientswithnon—sinailcel1lungcancer(NSCLC)．Methods：Randomizedcontrolled trials(RCT)evaluatingtheeffectivenessofEGFR—TKIscomparedwithchemotherapyasfirstlinetreatmentofthe EGFRmutation—selectedNSCLCwereobtainedfrom PubMed．theCochraneLibraryandEmbase．A1lliteratureswere assessedbytheinclusionandexclusioncriteria，qualitvassessmentanddataabstraction．TheMeta—analysiswasper— formedbyRevMan5．3．5(CochraneCollaboration)andSTATA12．0(STATACorp，Collegestation，TX)software andwascontrastedinEGFR —TKIs—treatmentoftheEGFRmutation—selectedNSCLCpatientscurativeeffect．The stabilityandreliabilitywereevaluatedbysensitivityanalysisandpublicationbiasanalysis．Results：A totalof5trials withl091patientswereincludedintheMeta—analysis．Comparedwiththechemotherapygroup，EGFR—TKIasfirst — linetherapygroup inEGFR mutation—selectedadvancedNSCLCpatientsshowedahigherORR andPFS，butthe OSdidnotsignificantlydiffer．Conclusion：Comparedwithchemotherapy，EGFRmutation—selectedadvancedNSCLC patientsreceivedmorebenefitsfrom EGFR—TKIsasfirst—linetreatment． 【Keywords】epidermalgrowthfactorreceptortyrosinekinaseinhibitors(EGFR—TKI)，non—smallcell